Page last updated: 2024-12-09

6-[(2-fluorophenyl)methyl]-2,4-dimethyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID654376
CHEMBL ID1084625
CHEBI ID93430
SCHEMBL ID12346483

Synonyms (25)

Synonym
6-(2-fluoro-benzyl)-2,4-dimethyl-4,6-dihydro-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one
6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one
MLS000076148
smr000000723
ml082
NCGC00031955-02
NCGC00031955-03
d8g ,
DB07628
CHEMBL1084625 ,
HMS2319B17
SCHEMBL12346483
842112-70-3
AKOS027255059
ncg31955
CHEBI:93430
mfcd05244579
SR-01000347474-1
sr-01000347474
AS-40571
Q27096849
6-(2-fluorobenzyl)-2,4-dimethyl-4h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5(6h)-one
6-[(2-fluorophenyl)methyl]-2,4-dimethylthieno[3,4]pyrrolo[1,3-d]pyridazin-5-one
bdbm50597709
10-[(2-fluorophenyl)methyl]-4,7-dimethyl-3-thia-7,10,11-triazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),4,11-tetraen-9-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
organosulfur heterocyclic compound
organic heterobicyclic compound
organonitrogen heterocyclic compoundAny organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency39.81070.631035.7641100.0000AID504339
ClpPBacillus subtilisPotency39.81071.995322.673039.8107AID651965
GLS proteinHomo sapiens (human)Potency7.07950.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency21.14460.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency1.12200.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926; AID938
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
pyruvate kinase PKLR isoform 1 [Homo sapiens]Homo sapiens (human)Potency1.53381.41251.41251.4125AID1543; AID1782; AID2562
pyruvate kinase PKM isoform aHomo sapiens (human)Potency0.16320.04017.459031.6228AID1540; AID1631; AID1634; AID1751; AID2533; AID2576
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency25.11890.00798.23321,122.0200AID2546
pyruvate kinase PKLR isoform 2Homo sapiens (human)Potency1.20622.51194.65797.9433AID1541; AID1781
neuropeptide S receptor isoform AHomo sapiens (human)Potency25.11890.015812.3113615.5000AID1461
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency31.62281.000010.475628.1838AID901
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pyruvate kinase PKMHomo sapiens (human)EC50 (µMol)0.03800.00050.59206.0000AID1881880
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pyruvate kinase PKMHomo sapiens (human)AC500.19450.03802.25409.1800AID482978; AID482981
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
programmed cell deathPyruvate kinase PKMHomo sapiens (human)
canonical glycolysisPyruvate kinase PKMHomo sapiens (human)
positive regulation of sprouting angiogenesisPyruvate kinase PKMHomo sapiens (human)
positive regulation of cytoplasmic translationPyruvate kinase PKMHomo sapiens (human)
glycolytic processPyruvate kinase PKMHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
magnesium ion bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingPyruvate kinase PKMHomo sapiens (human)
mRNA bindingPyruvate kinase PKMHomo sapiens (human)
protein tyrosine kinase activityPyruvate kinase PKMHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKMHomo sapiens (human)
protein bindingPyruvate kinase PKMHomo sapiens (human)
ATP bindingPyruvate kinase PKMHomo sapiens (human)
MHC class II protein complex bindingPyruvate kinase PKMHomo sapiens (human)
potassium ion bindingPyruvate kinase PKMHomo sapiens (human)
cadherin bindingPyruvate kinase PKMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionPyruvate kinase PKMHomo sapiens (human)
nucleusPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrionPyruvate kinase PKMHomo sapiens (human)
rough endoplasmic reticulumPyruvate kinase PKMHomo sapiens (human)
cytosolPyruvate kinase PKMHomo sapiens (human)
ciliumPyruvate kinase PKMHomo sapiens (human)
vesiclePyruvate kinase PKMHomo sapiens (human)
secretory granule lumenPyruvate kinase PKMHomo sapiens (human)
collagen-containing extracellular matrixPyruvate kinase PKMHomo sapiens (human)
extracellular exosomePyruvate kinase PKMHomo sapiens (human)
extracellular vesiclePyruvate kinase PKMHomo sapiens (human)
ficolin-1-rich granule lumenPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID482981Activation of human PKM2 assessed as pyruvate formation after 1 hr by fluorescent pyruvate kinase-lactate dehydrogenase coupled secondary assay2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482979Maximum activation of human PKM2 assessed as ATP product formation at 57 uM after 1 hr by luminescent pyruvate kinase-luciferase coupled assay relative to fructose-1,6-bis-phosphate2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482986Activation of PKM1 assessed as ATP product formation by luminescent pyruvate kinase-luciferase coupled assay2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482987Activation of PKR assessed as pyruvate formation by fluorescent pyruvate kinase-lactate dehydrogenase coupled assay2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482984Activation of PKL assessed as pyruvate formation by fluorescent pyruvate kinase-lactate dehydrogenase coupled assay2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482991Activation of human PKM2 assessed as effect on Km for ADP2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482983Activation of PKM1 assessed as pyruvate formation by fluorescent pyruvate kinase-lactate dehydrogenase coupled assay2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482988Activation of PKL assessed as ATP product formation by luminescent pyruvate kinase-luciferase coupled assay2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482978Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assay2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482982Activation of human PKM2 assessed as pyruvate formation at 57 uM after 1 hr by fluorescent pyruvate kinase-lactate dehydrogenase coupled assay relative to fructose-1,6-bis-phosphate2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482990Activation of human PKM2 assessed as reduction of Vmax for phosphoenolpyruvate2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482989Activation of human PKM2 assessed as reduction of Km for phosphoenolpyruvate2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID1881880Activation of PKM2 (unknown origin) Phe26, Tyr390, Glu397, Leu353 residues2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID482985Activation of PKR assessed as ATP product formation by luminescent pyruvate kinase-luciferase coupled assay2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482980Aqueous solubility in DMSO at pH 7.4 by quantitative nitrogen detection assay2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.28 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]